Trials / Recruiting
RecruitingNCT06704321
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
A Parallel, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial of the Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Both Men and Women with MASLD
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Valbiotis · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota among both men and women with MASLD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | TOTUM-448 | 16 weeks of TOTUM-448 supplementation (4.284g/day corresponding to 8 capsules per day) |
| DIETARY_SUPPLEMENT | Placebo | 16 weeks of placebo supplementation (8 capsules per day) |
Timeline
- Start date
- 2024-01-31
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2024-11-26
- Last updated
- 2024-11-26
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06704321. Inclusion in this directory is not an endorsement.